Alternatives to Traditional Unit Operations Are Now Available to Alleviate Very Real Logjams Due to the complexity of therapeutic protein purification, downstream bioprocess bottlenecks can arise from ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

What if blood type compatibility was no longer a limiting factor in emergency medicine, trauma response, or organ ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Standards organization says R2v3 certification entails accurately portraying operations of facilities receiving components and materials. SERI says qualifications for a non-R2v3 downstream vendor are ...

Purifying novel therapeutics remains a major challenge as increasingly complex molecules move towards the clinic. With Lonza, you can ensure optimal product quality and bring your molecules to the ...

Biopharmaceutical downstream processing requires precise control of multiple unit operations—from chromatography and filtration to viral inactivation—to ensure product quality and therapeutic efficacy ...

Authors: Nick Koumakis and Rut Besseling. Protein aggregation in downstream processing (DSP) is a product-quality concern and major process-performance issue ...

Modern semiconductor processes are extremely complicated and involve thousands of interacting individual process steps. During the development of these process steps, roadblocks and barriers are often ...